Academic Journal
Q1Therapeutic Advances in Psychopharmacology
About Therapeutic Advances in Psychopharmacology
Therapeutic Advances in Psychopharmacology is a scholarly journal published by SAGE Publications Inc.. SCImago 2025 lists it in Q1, with an SJR of 1.321 and H-index of 52.
Coverage: 2011-2026. Research categories: Pharmacology (medical) (Q1); Psychiatry and Mental Health (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2024-04-04. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Schizophrenia research and treatment; Treatment of Major Depression; Bipolar Disorder and Treatment; Tryptophan and brain disorders; Electroconvulsive Therapy Studies; Healthcare Decision-Making and Restraints.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Efficacy and safety of ecopipam for Tourette syndrome: An updated systematic review and meta-analysis of randomized controlled trials
Aasim Ali, Abdullah Shahid, Muhammad Usman, Asad Ullah Ansari et al.
2026-09 · DOI: 10.1177/20451253261487299A systematic review of case reports and case series of zolpidem in the diagnosis and treatment of catatonia
Niraj Ahuja, Harry Hackett, Joseph Thorne, Stuart Watson et al.
2026-09 · DOI: 10.1177/20451253261487038Expert opinion survey on the pharmacological treatment of insomnia in Japan (2025)
Hiromi Tagata, Saki Hattori, Hitoshi Sakurai, Hideaki Tani et al.
2026-09 · DOI: 10.1177/20451253261489651The pharmacotherapeutic use of clozapine in older adults: A narrative review
Kate Mulholland, Brian O’ Donoghue, Dan Siskind, Geraldine McCarthy et al.
2026-09 · DOI: 10.1177/20451253261481517Incidence of antidepressant withdrawal reactions: A prospective longitudinal cohort study in primary care patients
Andri Rennwald, Mark A. Horowitz, Oliver Senn, Stefan Neuner-Jehle et al.
2026-09 · DOI: 10.1177/20451253261492597Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context
Aristomenis G. Alevizopoulos, Vasileios Vasilakos, Iakovos Kritikos, Maria Alevizopoulou et al.
2026-09 · DOI: 10.1177/20451253261457548Anticholinergic burden and its predictors among patients with schizophrenia in Northwest Ethiopia: An institutional-based cross sectional study
Fasil Bayafers Tamene, Getachew Yitayew Tarekegn, Tilaye Arega Moges, Samuel Berihun Dagnew et al.
2026-08 · DOI: 10.1177/20451253261481515The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review
Feng Ji, Lijuan Ma, Xuning Shen, Xiaoling Liang et al.
2026-08 · DOI: 10.1177/20451253261478086Lithium-induced blepharospasm in a middle-aged woman with recurrent depressive disorder: a case report
Maria del Rosario Arevalo Bazalar, Jayamal De Silva
2026-08 · DOI: 10.1177/20451253261467607Therapeutic apartheid: a cross-sectional assessment of estimated cost, accessibility, affordability, and availability among psychotropic medications across 25 regions
Javier A. Flores-Cohaila, Luis Arturo Vílchez Salcedo, Carlos Alexis Salgado Valenzuela, Cesar Li Amenero et al.
2026-08 · DOI: 10.1177/20451253261440374Consent beyond the written form: Implications for ketamine trials in the Philippines
Abegail A. Pagallaman, John Noel E. Fermin
2026-08 · DOI: 10.1177/20451253261486613Same sample, different result: Variation in clozapine assay measurement in four UK laboratories
Matthew Atkins, James Fritz, Mary Rose Hilaire, David Taylor et al.
2026-08 · DOI: 10.1177/20451253261473111Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?
Fabrice Berna, Guillaume Durand, Rémy Boussageon, Julien Nizard et al.
2026-08 · DOI: 10.1177/20451253261436150Psychoactive drug use and substance-induced psychosis: Emerging challenges in a low-middle-income country
Nabin Pathak, Sunil Shrestha
2026-08 · DOI: 10.1177/20451253261473921Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study)
Pierre-Michel Llorca, Anne Sauvaget, Emilie Olié, Lila Mékaoui et al.
2026-08 · DOI: 10.1177/20451253261463652Clinical response to clozapine in Black people with psychosis: A secondary analysis of an open-label clinical trial
Allison S. Brandt, Gopal Vyas, Taiwo Oduguwa, Adeola O. Adebayo et al.
2026-08 · DOI: 10.1177/20451253261481518Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies
Minahil Rasul, Ahmad Hassan, Ubaid Ur Rehman, Muhammad Sarmad et al.
2026-08 · DOI: 10.1177/20451253261473919Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review
Martin Krsak, David Sparrow, Bernard Rosner, Deborah DeMolles et al.
2026-07 · DOI: 10.1177/20451253261470523A qualitative exploration of perspectives on taking lithium supplements
Madeleine Bloomfield, Lily Chebabo-Manning, Rebecca Strawbridge
2026-07 · DOI: 10.1177/20451253261462260Lithium in the management of suicide: a formidable force in the fight against a fatal foe
Gurubhaskar Shivakumar, Kinga Szymaniak, Erica Bell, Gin S. Malhi et al.
2026-07 · DOI: 10.1177/20451253261467801Reviews
Community Reviews
Version History
September 25, 2026 at 7:35 am
September 25, 2026